GSK 219867

Drug Development Trials

About the trial

A Phase 2, Parallel Group, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, Multicenter Treatment Study to Evaluate the Efficacy and Safety of GSK457226 [AL101] Intravenous infusion Compared with placebo in Patients with Early Alzheimer’s Disease.